Follicle-stimulating hormone, interleukin-1, and bone density in adult women

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 3, 2010, Pages

  Cannon, Joseph G ^a   Cortez Cooper, Miriam ^a   Meaders, Eric ^a   Stallings, Judith ^a   Haddow, Sara ^a   Kraj, Barbara ^a   Sloan, Gloria ^a   Mulloy, Anthony ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Inhibin; Leptin; Physical activity

Indexed keywords

FOLLITROPIN; FOLLITROPIN RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MONONUCLEAR CELL; OSTEOLYSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGING; BODY COMPOSITION; BONE DENSITY; CELLS, CULTURED; ESTRADIOL; FEMALE; FLOW CYTOMETRY; FOLLICLE STIMULATING HORMONE, HUMAN; FOLLICULAR PHASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LEPTIN; LUTEINIZING HORMONE; MIDDLE AGED; MONOCYTES; MOTOR ACTIVITY; RECEPTORS, INTERLEUKIN-1; REGRESSION ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77749328944     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00728.2009     Document Type: Article

References (49)

1. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1 receptor antagonist: The Danish Osteoporosis Prevention Study. J Bone Miner Res 15: 1545-1554, 2000.
2. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol 29, Suppl 65: 16-21, 2002.
3. Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin Immunol Immunopathol 66: 201-211, 1993.
4. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findley DM, Evdokiou A, Zannettino ACW. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 21: 1339-1349, 2006.
5. Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, de Talance N, Doucet B, Jeandel C. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endo Metab 87: 1030-1035, 2002.
6. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, Dennerstein L. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-bsed cohort of women. J Clin Endo Metab 84: 4025-4030, 1999.
7. Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL. Interleukin-1β, interleukin-1 receptor antagonist and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 17: 253-261, 1997.
8. Cannon JG, Guion J, Sloan GJ, Stallings J. Follicle-stimulating hormone receptor expression on leukocytes. FASEB J 20: A1285, 2006.
9. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnare: 12-country reliability and validity. Med Sci Sports Exerc 35: 1381-1395, 2003.
10. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 27: 519-550, 2009.
11. Evans DB, Bunning RA, Russell RG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun 166: 208-216, 1990.
12. Fernandez-Botran R. Soluble cytokine receptors: Basic immunology and clinical applications. Crit Rev Clin Lab Sci 36: 165-244, 1999.
13. Findlay JK, Drummond AE. Regulation of the FSH receptor in the ovary. Trends Endocrinol Metab 10: 183-188, 1999.
14. Flynn A. Stimulation of interleukin-1 production from placental monocytes. Lymphokine Res 3: 1-5, 1984.
15. Gabay C, Dreyer MG, Pellegrinelli N, Chicheportiche R, Meier CA. Leptin directly induces the secretion of inteleukin 1 receptor antagonist in human monocytes. J Clin Endo Metab 86: 783-791, 2001.
16. Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 63: 456-458, 1998.
17. Guthrie JR, Ebeling PR, Hopper JL, Barrett-Connor E, Dennerstein L, Dudley EC, Burger HG, Wark JD. A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int 8: 282-290, 1998.
18. Hall JE. Neuroendocrine physiology of the early and late menopause. Endocrinol Metab Clin N Am 33: 637-659, 2004.
19. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TJ, Collier GR, Nicholson GC. Leptin inhibits osteoclast generation. J Bone Miner Res 17: 200-209, 2002.
20. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257: 88-91, 1992.
21. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247: 84-93, 1999.
22. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94: 2397-2406, 1994.
23. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: Accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endo Metab 81: 1038-1045, 1996.
24. Komorowski J, Jankiewicz J, Stepien H. Effects of thyrotropin, follicle stimulating hormone and luteinizing hormone on sIL-2R in vitro secretion from human peripheral blood mononuclear cells. Cytobios 93: 43-48, 1998.
25. Komorowski J, Pawlikowski M, Stepien H. Pituitary glycoprotein hormones and interleukin secretion. Ann NY Acad Sci 762: 429-431, 1995.
26. Lacey DL, Grosso LE, Moser SA, Erdmann J, Tan HL, Pacifici R, Villareal DT. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 91: 1731-1742, 1993.
27. LaPolt PS, Tilly JL, Aihara T, Nishimori K, Hsueh AJW. Gonadotropin-induced up- and down-regulation of ovarian follicle-stimulating hormone (FSH) receptor gene expression in immature rats: Effects of pregnant mare's serum gonadotropin, human chorionic gonadotropin, and recombinant FSH. Endocrinology 130: 1289-1295, 1992.
28. Mancinelli R, Onori P, Gaudio E, DeMorrow S, Franchitto A, Francis H, Glaser S, Carpino G, Venter J, Alvaro D, Kopriva S, White M, Kossie A, Savage J, Alpini G. Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. Am J Physiol Gastrointest Liver Physiol 297: G11-G26, 2009.
29. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodeling. N Engl J Med 332: 305-311, 1995.
30. Minegishi T, Tano M, Igarashi M, Rokukawa Y, Abe Y, Ibuki Y, Miyamoto K. Expression of follicle-stimulating hormone receptor in human ovary. Eur J Clin Invest 27: 469-474, 1997.
31. Mori H, Nakagawa M, Itoh N, Wada K, Tamaya T. Danazol suppresses the production of interleukin-1β and tumor necrosis factor by human monocytes. Am J Repro Immunol 24: 45-50, 1990.
32. Nanes MS. Tumor necrosis factor-α: Molecular and cellular mechanisms in skeletal pathology. Gene 321: 1-15, 2003.
33. Pacifici R, Vannice JL, Rifas L, Kimble RB. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/progesterone therapy. J Clin Endo Metab 77: 1135-1141, 1993.
34. Polan ML, Daniele A, Kuo A. Gonadal steroids modulate human monocyte interleukin-1 (IL-1) activity. Fertil Steril 49: 964-968, 1988.
35. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13: 1189-1196, 1994.
36. Prior JC. FSH and bone: important physiology or not? Trends Mol Med 13: 1-3, 2006.
37. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 19: 397-428, 1998.
38. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 15: 1965-1973, 2000.
39. Richards JS, Ireland JJ, Rao MC, Bernath GA, Midgley ARJ, Reichert LEJ. Ovarian follicular development in the rat: Hormonal receptor regulation by estradiol, follicle stimulating hormone and luteinizing hormone. Endocrinology 99: 1562-1570, 1976.
40. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endo Metab 81: 1495-1501, 1996.
41. Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass. A study about the time of menopause. J Clin Invest 80: 1261-1269, 1987.
42. Sowers MF, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, Neer RM, Johnston J, Ettinger B. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endo Metab 91: 1261-1267, 2006.
43. Sowers MF, Zheng H, McConnell D, Nan B, Harlow S, Randolph Jr JF. Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endo Metab 93: 3958-3964, 2008.
44. Sowers MR, Finkelstein JS, Ettinger B, Bondarenko I, Neer RM, Cauley JA, Sherman S, Greendale GA. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 14: 44-52, 2003.
45. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass. Cell 125: 247-260, 2006.
46. Thomas T, Burguera B, Melton IIILJ, Atkinson EJ, O'Fallon WM, Riggs BL, Khosla S. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29: 114-120, 2001.
47. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140: 1630-1638, 1999.
48. Vihko KK, Kujansuu E, Morsky P, Huhtaniemi I, Punnonen R. Gonadotropins and gonadotropin receptors during the perimenopause. Eur J Endocrinol 134: 357-361, 1996.
49. Zaidi S, Zhu LL, Mali R, Iqbal J, Yang G, Zaidi M, Sun L. Regulation of FSH receptor promoter activation in the osteoclast. Biochem Biophys Res Commun 361: 910-915, 2007.